1. Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, et al. Guillain-Barre syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118 ( Pt 3):597–605.
2. Feasby TE, Gilbert JJ, Brown WF, Bolton CF, Hahn AF, Koopman WF, et al. An acute axonal form of Guillain-Barre polyneuropathy. Brain. 1986;109 ( Pt 6):1115-26.
3. McKhann GM, Cornblath DR, Griffin JW, Ho TW, Li CY, Jiang Z, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993;33 4:333 − 42.
4. Yuki N, Hartung HP. Guillain-Barre syndrome. N Engl J Med. 2012;366 24:2294 − 304.
5. Kuwabara S, Yuki N. Axonal Guillain-Barre syndrome: concepts and controversies. Lancet Neurol. 2013;12 12:1180-8.
6. Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, et al. A bacterium lipopolysaccharide that elicits Guillain-Barre syndrome has a GM1 ganglioside-like structure. J Exp Med. 1993;178 5:1771-5.
7. Kuwabara S, Yuki N, Koga M, Hattori T, Matsuura D, Miyake M, et al. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barre syndrome. Ann Neurol. 1998;44 2:202-8.
8. Capasso M, Caporale CM, Pomilio F, Gandolfi P, Lugaresi A, Uncini A. Acute motor conduction block neuropathy Another Guillain-Barre syndrome variant. Neurology. 2003;61 5:617 − 22.
9. Kuwabara S, Asahina M, Koga M, Mori M, Yuki N, Hattori T. Two patterns of clinical recovery in Guillain-Barre syndrome with IgG anti-GM1 antibody. Neurology. 1998;51 6:1656-60.
10. Kokubun N, Nishibayashi M, Uncini A, Odaka M, Hirata K, Yuki N. Conduction block in acute motor axonal neuropathy. Brain. 2010;133 10:2897 − 908.
11. Uncini A, Manzoli C, Notturno F, Capasso M. Pitfalls in electrodiagnosis of Guillain-Barre syndrome subtypes. J Neurol Neurosurg Psychiatry. 2010;81 10:1157-63.
12. Hiraga A, Kuwabara S, Ogawara K, Misawa S, Kanesaka T, Koga M, et al. Patterns and serial changes in electrodiagnostic abnormalities of axonal Guillain-Barre syndrome. Neurology. 2005;64 5:856 − 60.
13. Kuwabara S, Ogawara K, Misawa S, Koga M, Mori M, Hiraga A, et al. Does Campylobacter jejuni infection elicit "demyelinating" Guillain-Barre syndrome? Neurology. 2004;63 3:529 − 33.
14. Brown WF, Feasby TE. Conduction block and denervation in Guillain-Barre polyneuropathy. Brain. 1984;107 ( Pt 1):219 − 39.
15. Baba M, Matsunaga M. Recovery from acute demyelinating conduction block in the presence of prolonged distal conduction delay due to peripheral nerve constriction. Electromyogr Clin Neurophysiol. 1984;24 7:611-7.
16. Clouston PD, Kiers L, Zuniga G, Cros D. Quantitative analysis of the compound muscle action potential in early acute inflammatory demyelinating polyneuropathy. Electroencephalogr Clin Neurophysiol. 1994;93 4:245 − 54.
17. Hosokawa T, Nakajima H, Unoda K, Yamane K, Doi Y, Ishida S, et al. An electrophysiological classification associated with Guillain-Barre syndrome outcomes. J Neurol. 2014;261 10:1986-93.
18. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol. 1990;27 Suppl:S21-4.
19. Yuki N, Kokubun N, Kuwabara S, Sekiguchi Y, Ito M, Odaka M, et al. Guillain-Barre syndrome associated with normal or exaggerated tendon reflexes. J Neurol. 2012;259 6:1181-90.
20. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978;2 8093:750-3.
21. Kimura J. electrodiagnosis in diseases of nerve and muscle: principles and practice. 2nd edn. Philadelphia: F.A. Davis; 1989.
22. Isose S, Kuwabara S, Kokubun N, Sato Y, Mori M, Shibuya K, et al. Utility of the distal compound muscle action potential duration for diagnosis of demyelinating neuropathies. J Peripher Nerv Syst. 2009;14 3:151-8.
23. Kalita J, Misra UK, Das M. Neurophysiological criteria in the diagnosis of different clinical types of Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2008;79 3:289 − 93.
24. Kuwabara S, Ogawara K, Mizobuchi K, Koga M, Mori M, Hattori T, et al. Isolated absence of F waves and proximal axonal dysfunction in Guillain-Barre syndrome with antiganglioside antibodies. J Neurol Neurosurg Psychiatry. 2000;68 2:191-5.
25. Feasby TE, Hahn AF, Brown WF, Bolton CF, Gilbert JJ, Koopman WJ. Severe axonal degeneration in acute Guillain-Barre syndrome: evidence of two different mechanisms? J Neurol Sci. 1993;116 2:185 − 92.
26. Griffin JW, Li CY, Ho TW, Tian M, Gao CY, Xue P, et al. Pathology of the motor-sensory axonal Guillain-Barre syndrome. Ann Neurol. 1996;39 1:17–28.
27. Hosokawa T, Nakajima H, Unoda K, Yamane K, Doi Y, Ishida S, et al. Serial electrophysiological findings in Guillain-Barre syndrome not fulfilling AIDP or AMAN criteria. J Neurol. 2016;263 9:1709-18.
28. Scott AJ, Duncan R, Henderson L, Jamal GA, Kennedy PG. Acute rhabdomyolysis associated with atypical Guillain-Barre syndrome. Postgrad Med J. 1991;67 783:73 − 4.
29. Satoh J, Okada K, Kishi T, Nagayama S, Kuroda Y. Cramping pain and prolonged elevation of serum creatine kinase levels in a patient with Guillain-Barre syndrome following Campylobacter jejuni enteritis. Eur J Neurol. 2000;7 1:107-9.
30. Saxena A, Singh V, Verma N. Guillain-Barre syndrome complicated by acute fatal rhabdomyolysis. Indian J Crit Care Med. 2014;18 4:241-3.
31. Ropper AH, Shahani BT. Pain in Guillain-Barre syndrome. Arch Neurol. 1984;41 5:511-4.
32. Ho TW, Hsieh ST, Nachamkin I, Willison HJ, Sheikh K, Kiehlbauch J, et al. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology. 1997;48 3:717 − 24.
33. Kane NM, Oware A. Nerve conduction and electromyography studies. J Neurol. 2012;259 7:1502-8.